🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchBimagrumab + semaglutide — my results so far Page 4

Bimagrumab + semaglutide — my results so far

MaxMetOK Fri, Jan 9, 2026 at 3:38 PM 32 replies 1,200 viewsPage 4 of 7
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
Jan 11, 2026 at 5:24 AM#16

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Correct me if the detail matters more than I have assumed.

42 15MikeFit_NJ, InsuranceTom, WendyG_ATL and 39 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Jan 11, 2026 at 8:19 AM#17

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

43 16Admin, Dr.Martinez, mike_mod and 40 others
Reply Quote Save Share Report
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Jan 11, 2026 at 11:14 AM#18

Following on from SleepDoc_PDX — and this may be the naive question:

How long did you give it before you decided it was working?

44 17kim_atl_prep, sarah_TO, wendy_avl and 41 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Jan 11, 2026 at 2:09 PM#19
FDA_TrackerJim said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

Pushing back on FDA_TrackerJim here. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

Last edited: Jan 11, 2026 at 3:09 PM
45 18VendorMark, COA_Karl, MikeFit_NJ and 42 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jan 11, 2026 at 5:04 PM#20

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.

17 15PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 14 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register